Comparison of Pediatric vs Adult Acute Lymphoblastic Leukemia (ALL)
| Feature | Pediatric ALL | Adult ALL |
|---|---|---|
| Epidemiology | Most common childhood cancer (~25% of pediatric malignancies). Peak incidence: 2–5 years. | Less common in adults (~20% of adult leukemias). Incidence increases with age. Median age ~30–40, but can occur up to elderly. |
| Gender Distribution | Slight male predominance. | Slight male predominance as well. |
| Etiology / Risk Factors | Associated with Down syndrome, Li-Fraumeni, Bloom, Ataxia-telangiectasia. | Environmental exposures (radiation, benzene), prior chemotherapy, hematologic disorders (e.g., myelodysplasia). |
| Cell Lineage | ~80–85% B-cell lineage, 15–20% T-cell lineage. | B-cell (~75%) and T-cell (~25%). Higher proportion of T-cell ALL in adults. |
| Genetic Abnormalities | Favorable: ETV6-RUNX1 (t(12;21)), Hyperdiploidy. Unfavorable: Hypodiploidy, MLL rearrangements (infants). |
Poorer genetics: BCR-ABL1 (Philadelphia chromosome t(9;22)), MLL rearrangements, hypodiploidy, iAMP21. Ph+ ALL is common (~25% of adult ALL). |
| Clinical Presentation | Bone marrow failure: anemia, thrombocytopenia, neutropenia. Organ infiltration: hepatosplenomegaly, lymphadenopathy, bone pain. CNS/testicular involvement more common in children. |
Similar marrow failure features. CNS/testicular involvement less frequent at diagnosis. Higher leukocyte counts at presentation. |
| Prognostic Factors | Age 1–10 years favorable; WBC <50,000 favorable. Cytogenetics strongly predictive. Response to therapy (MRD at day 29) most critical. |
Age <35 favorable. Ph+ or complex karyotype = poor prognosis. MRD status critical for remission & transplant decision. |
| Treatment Approach | Multi-phase chemotherapy (Induction, Consolidation, Maintenance). Pediatric regimens are more intensive and prolonged (~2–3 years total). Intrathecal CNS prophylaxis essential. |
Similar phases, but tolerability is poorer. Use of pediatric-inspired regimens in young adults improves survival vs traditional adult regimens. Tyrosine kinase inhibitors (TKIs: imatinib, dasatinib, ponatinib) standard for Ph+ ALL. Allogeneic stem cell transplant (allo-SCT) considered earlier. |
| Targeted / Novel Therapies | Blinatumomab (BiTE, CD19), Inotuzumab ozogamicin (CD22), CAR-T (tisagenlecleucel) used in relapsed/refractory disease. | Same novel therapies but used more frequently due to higher relapse and poor prognosis. CAR-T widely used in relapsed adult B-ALL. |
| CNS Prophylaxis | Intrathecal methotrexate, cytarabine, hydrocortisone ± high-dose systemic methotrexate. Cranial irradiation avoided due to long-term toxicity. | Intrathecal chemo still required. Cranial irradiation less common but sometimes used in high-risk cases. |
| Treatment Duration | ~2–3 years (long maintenance phase with 6-MP + MTX). | Shorter maintenance (~2 years max). Adults tolerate prolonged therapy poorly. |
| Treatment Tolerance | Generally better tolerance, lower induction mortality (<2%). | Higher induction mortality (up to 10%), more complications (infections, organ toxicity). |
| Overall Survival (OS) | Excellent: ~85–90% cure rate in high-income countries. | Poorer: ~40–50% long-term survival in younger adults; <20% in elderly. |
| Relapse Patterns | Common sites: bone marrow, CNS, testes. | Relapse more often marrow-based, CNS/testicular less common. |
| Long-Term Complications | Growth delay, endocrine dysfunction, neurocognitive effects, secondary malignancies. | Higher risk of treatment-related mortality, chronic GVHD post-transplant, and secondary AML/MDS. |
Key Takeaways for Oncology Pharmacists:
- Pediatric ALL is highly curable with multi-agent chemo, and genetic subtypes strongly guide prognosis.
- Adult ALL is biologically more aggressive, with higher incidence of poor-risk genetics (esp. Ph+).
- Ph+ ALL management = TKI + chemo ± transplant.
- Novel therapies (CAR-T, Blinatumomab, Inotuzumab) have shifted the paradigm, especially in relapsed/refractory ALL for both age groups.
Pediatric vs Adult ALL Chemotherapy Regimens
| Treatment Phase | Pediatric ALL (standard/high risk protocols, e.g. COG) | Adult ALL (CALGB, Hyper-CVAD, pediatric-inspired regimens) |
|---|---|---|
| Induction (goal: remission <5% blasts in marrow) | 4–6 weeks • Vincristine • Dexamethasone or Prednisone • L-Asparaginase (PEG-asparaginase preferred) • ± Anthracycline (Daunorubicin/Doxorubicin) in higher risk • Intrathecal Methotrexate (± Cytarabine, Hydrocortisone) |
4–6 weeks • Vincristine • Prednisone or Dexamethasone • Anthracycline (Daunorubicin/Idarubicin) • Cyclophosphamide • L-Asparaginase (used less in adults due to hepatotoxicity/pancreatitis risk) • Intrathecal chemo |
| Consolidation / Intensification (eradicate residual disease, prevent relapse) | Multi-agent, several months: • High-dose Methotrexate ± Leucovorin rescue • Cytarabine • 6-Mercaptopurine (6-MP) • Cyclophosphamide • Vincristine + Asparaginase blocks • CNS prophylaxis continues |
Cycles of Hyper-CVAD alternating with high-dose MTX + Cytarabine • Cyclophosphamide • Vincristine • Adriamycin (doxorubicin) • Dexamethasone (Cycle A) Alternate with: • High-dose MTX + Cytarabine (Cycle B) CNS prophylaxis with intrathecal MTX/ARA-C |
| Interim Maintenance / Delayed Intensification (unique to pediatrics) | • Alternating MTX, 6-MP, Vincristine, Asparaginase • “Delayed Intensification” phase improves outcomes significantly in children |
Typically not included in adult protocols due to tolerability limits |
| Maintenance (prevent relapse) | 18–24 months: • Daily 6-MP (oral) • Weekly Methotrexate (oral or IM) • Monthly Vincristine + Prednisone pulses • Continued intrathecal chemo |
Shorter (~12–18 months): • Daily 6-MP • Weekly MTX • ± Vincristine/Prednisone pulses • Some adult protocols proceed to Allo-SCT in CR1 if high risk |
| Targeted Therapy | • CAR-T (tisagenlecleucel) for relapsed/refractory B-ALL • Blinatumomab (CD19 BiTE) • Inotuzumab ozogamicin (CD22 antibody-drug conjugate) |
• TKIs (Imatinib, Dasatinib, Ponatinib) for Ph+ ALL (added from induction onward) • Same novel therapies (CAR-T, Blinatumomab, Inotuzumab) widely used in relapsed/refractory setting |
| Transplant (Allo-SCT) | Reserved for very high-risk or relapsed pediatric ALL. Cure rates are high with chemo alone. | Considered earlier (first remission) for Ph+ ALL, high-risk genetics, or persistent MRD. |
Key Points for Oncology Pharmacists:
- Pediatric regimens → longer, include delayed intensification and prolonged maintenance (2–3 years).
- Adult regimens → shorter, often Hyper-CVAD–based, less asparaginase, earlier transplant consideration.
- Ph+ ALL → Adults almost always get TKIs, children get them too but less frequently (since Ph+ is rarer in pediatrics).
- MRD (minimal residual disease) is now the most important factor guiding escalation to transplant in both groups.